CD177 and cancer: Tumour angiogenesis is a well-established target for anti-cancer therapeutics through targeting of growth factors, their cell surface receptors and associated signalling pathways [3], however, tumour lymphangiogenesis is yet to be clinically validated as a therapeutic target.